203 related articles for article (PubMed ID: 29617171)
1. Lenvatinib-induced renal failure: two first-time case reports and review of literature.
Cavalieri S; Cosmai L; Genderini A; Nebuloni M; Tosoni A; Favales F; Pistillo P; Bergamini C; Bossi P; Licitra L; Locati LD; Alfieri S
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):379-385. PubMed ID: 29617171
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
4. Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.
Masaki C; Sugino K; Kobayashi S; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Int J Clin Oncol; 2020 Jul; 25(7):1278-1284. PubMed ID: 32347432
[TBL] [Abstract][Full Text] [Related]
5. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.
Denaro N; Latina A; Cesario F; Bramardi F; Corrado L; Borretta G; Merlano MC
Oncology; 2019; 97(4):206-210. PubMed ID: 31390629
[TBL] [Abstract][Full Text] [Related]
7. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
8. Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib.
Wassermann J; Bagnis CI; Leenhardt L; Ederhy S; Buffet C
Expert Opin Drug Saf; 2022 Nov; 21(11):1401-1410. PubMed ID: 36458701
[TBL] [Abstract][Full Text] [Related]
9. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N; Glen H; Gerrard G; Good J; Lei M; Lyon AR; Strachan M; Wadsley J; Newbold K
Clin Oncol (R Coll Radiol); 2020 May; 32(5):e145-e153. PubMed ID: 31843241
[TBL] [Abstract][Full Text] [Related]
10. Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.
Colombo C; Ceruti D; De Leo S; Bilo G; Trevisan M; Giancola N; Moneta C; Parati G; Persani L; Fugazzola L
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37097040
[TBL] [Abstract][Full Text] [Related]
11. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
12. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
13. Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review.
Pham B; Kwon SM; Castillo DR; Majeed Y; Ahmad S; Hou J; Ganesan L; Mohammad S; Cao H
J Oncol Pharm Pract; 2022 Dec; 28(8):1930-1935. PubMed ID: 35369811
[TBL] [Abstract][Full Text] [Related]
14. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
Hayato S; Shumaker R; Ferry J; Binder T; Dutcus CE; Hussein Z
Cancer Chemother Pharmacol; 2018 Dec; 82(6):971-978. PubMed ID: 30244318
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
20. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
